In cohort II, renal cancer patients with high EPB41L4A-AS2 expression had better OS than those with low EPB41L4A-AS2 expression, which was consistent with our findings in breast cancer patients (p < 0.001, Supplementary Figure S10). Here, EPB41L4A is linked to breast carcinoma.